TY - JOUR
T1 - Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide
AU - Deliliers, Giorgio Lambertenghi
AU - Annaloro, Claudio
AU - Marconi, Maurizio
AU - Soligo, Davide
AU - Morandi, Paolo
AU - Luchesini, Camilla
AU - Tagliaferri, Elena
AU - Della Volpe, Aldo
PY - 2002/10
Y1 - 2002/10
N2 - Although high-dose cyclophosphamide (HD-CTX) is commonly used as a mobilising regimen for autologous peripheral blood stem cell (PBSC) collection, significant morbidity and insufficient harvesting may complicate the procedure. Alternative regimens and lower doses of cyclophosphamide (CTX) have been investigated as possible ways of overcoming these difficulties. Low-dose CTX (1.5 g/m2) was administered to 102 lymphoma patients as an autologous PBSC mobilising regimen. The collection of 6 × 106 CD34+ cells/kg was chosen as the target of the apheresis sessions, whereas 3 × 106/kg were considered the minimum necessary to perform autologous stem cell transplantation (ASCT) safely. The apheretic sessions were started a median of eight days after CTX administration; a median of two aphereses was required. More than 6 × 106 CD34+ cells/kg were collected from 78 patients, between 3 and 6 × 106/kg from 19, and fewer than 3 × 106/kg from 5, two of whom underwent bone marrow harvesting and one a successful second PBSC harvesting session using the same mobilising regimen. Eighty-two patients underwent autografting, six of whom received a second transplant after relapse (five using autologous PBSCs coming from the first apheretic course). Low-dose CTX proved to be a safe and effective regimen for autologous PBSC mobilization and also compared favourably with alternative regimens in terms of the rate of harvesting insufficiency. This does not imply that low-dose CTX is the best mobilising regimen for all patients, and the identification of prognostic factors predicting mobilising potential may help in choosing the best individualised regimen.
AB - Although high-dose cyclophosphamide (HD-CTX) is commonly used as a mobilising regimen for autologous peripheral blood stem cell (PBSC) collection, significant morbidity and insufficient harvesting may complicate the procedure. Alternative regimens and lower doses of cyclophosphamide (CTX) have been investigated as possible ways of overcoming these difficulties. Low-dose CTX (1.5 g/m2) was administered to 102 lymphoma patients as an autologous PBSC mobilising regimen. The collection of 6 × 106 CD34+ cells/kg was chosen as the target of the apheresis sessions, whereas 3 × 106/kg were considered the minimum necessary to perform autologous stem cell transplantation (ASCT) safely. The apheretic sessions were started a median of eight days after CTX administration; a median of two aphereses was required. More than 6 × 106 CD34+ cells/kg were collected from 78 patients, between 3 and 6 × 106/kg from 19, and fewer than 3 × 106/kg from 5, two of whom underwent bone marrow harvesting and one a successful second PBSC harvesting session using the same mobilising regimen. Eighty-two patients underwent autografting, six of whom received a second transplant after relapse (five using autologous PBSCs coming from the first apheretic course). Low-dose CTX proved to be a safe and effective regimen for autologous PBSC mobilization and also compared favourably with alternative regimens in terms of the rate of harvesting insufficiency. This does not imply that low-dose CTX is the best mobilising regimen for all patients, and the identification of prognostic factors predicting mobilising potential may help in choosing the best individualised regimen.
KW - Autologous transplantation
KW - Low-dose CTX
KW - PBSC mobilisation
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=1842845355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842845355&partnerID=8YFLogxK
U2 - 10.1080/1042819021000015899
DO - 10.1080/1042819021000015899
M3 - Article
C2 - 12481891
AN - SCOPUS:1842845355
VL - 43
SP - 1957
EP - 1960
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 10
ER -